1. Home
  2. ABAT vs TLSI Comparison

ABAT vs TLSI Comparison

Compare ABAT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Battery Technology Company

ABAT

American Battery Technology Company

HOLD

Current Price

$1.34

Market Cap

302.3M

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$3.60

Market Cap

250.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABAT
TLSI
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
302.3M
250.0M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ABAT
TLSI
Price
$1.34
$3.60
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.00
★ $10.40
AVG Volume (30 Days)
★ 2.5M
206.3K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
$45.86
$17.65
Revenue Next Year
N/A
$40.27
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$1.37
$2.20
52 Week High
$6.01
$7.95

Technical Indicators

Market Signals
Indicator
ABAT
TLSI
Relative Strength Index (RSI) 18.60 30.66
Support Level N/A $3.05
Resistance Level $2.41 $3.68
Average True Range (ATR) 0.11 0.21
MACD -0.04 -0.02
Stochastic Oscillator 1.32 7.07

Price Performance

Historical Comparison
ABAT
TLSI

About ABAT American Battery Technology Company

American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. The company also advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company focuses on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: